Rasna Therapeutics, an oncology development stage biotech company, in which Prof. Roberto Pellicciari (TES Pharma CEO) is a founding partner, goes public on the OTC Market

 

Rasna Therapeutics, Inc. Completes Reverse Merger and Becomes a Publicly Traded Company

August 17, 2016 07:00 AM Eastern Daylight Time

NEW YORK–(BUSINESS WIRE)–Rasna Therapeutics, Inc., a development stage biotechnology company focused on the development of cancer drugs, today announced the successful completion of its merger with the Active With Me, Inc. (OTC:ATVM). The combined company intends to change its name to Rasna Therapeutics, Inc. and will trade on the OTC Markets under the symbol “ATVM.” The Company intends to submit an application to change its trading symbol.
“Becoming a public company is a key element of our growth strategy, and the completion of this reverse merger is a significant accomplishment for Rasna Therapeutics,” said James Tripp, Acting Chief Executive Officer of Rasna, “We believe that this breakthrough program may have significant benefits across all forms of leukemia. Our NPM1 program targets the sub-set of acute myeloid leukemia (AML) patients with the NPM1 mutation and may also benefit the general AML population. We are aiming to have a lead candidate identified by 2017.”
Rasna Therapeutics is engaged in modulating the molecular targets LSD1 and NPM1, which are implicated in the disease progression of leukemia and lymphoma. Rasna was formed in 2013 by biotechnology entrepreneur Gabriele Cerrone, together with distinguished scientists, Dr. Roberto Pellicciari, a medicinal chemist and the scientific founder of Intercept Pharmaceuticals, Inc. (ICPT), and Dr. Brunangelo Falini, a physician and hematologist.
Rasna’s scientific team is comprised of world-renowned experts in blood cancers such as leukemia and lymphoma. Dr. Riccardo Dalla-Favera is a board member of Rasna and the director of the Institute for Cancer Genetics at Columbia University and a member of the National Academy of Sciences, Dr. Falini is the Director of the Hematology Institute at the University of Perugia, Italy and Dr. Pier Giuseppe Pelicci, a collaborator with Rasna, is the Chairman of the Department of Experimental Oncology at the European Institute of Oncology.

About Rasna Therapeutics, Inc.
Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia (AML), leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna’s focus on inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD1 regulators that have shown appropriate effects on the LSD1 gene in-vitro and in IND-enabling pre-clinical studies.

Rasna Therapeutics Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Rasna Therapeutics’ business and Rasna Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contacts
Rasna Therapeutics Inc.
James Tripp, +1 212-297-6288
Acting Chief Executive Officer
jtripp@rasna.com

 

Open Position: Molecular Biology Scientist

 

Molecular Biology Scientist
Principal skills requested: Protein Production, Sequencing, Assay Development

TES Pharma is seeking a highly motivated and dedicated protein production and assay development Scientist looking to develop themselves in an energetic research environment. The successful candidate will work in a multi-disciplinary team to contribute expertise in the expression, purification, and characterization of recombinant proteins and DNA. The preferred candidate should also have demonstrated experience in assay development and assay validation for protein-protein interaction, receptor, and enzyme primary assays.

The successful candidate is expected to conduct independent lab work, that contributes to their team to advance research projects. A strong background in molecular biology, protein expression, and purification skills is therefore required.

Your Profile
You’re someone with a strong desire to apply and develop your skillset in the challenging and dynamic environment of a successful science-driven drug discovery company.
You should bring the following skills:
Experience in molecular biology, including PCR, DNA subcloning, and site directed mutagenesis.
Experience with protein expression in bacterial and/or baculovirus expression systems, using AKTA instruments
Experience with cell cultures and gene expression profiling would be preferable.
A demonstrated track record in assay development and validation would be a strong plus.

You should be highly interactive and:
Participate in group meetings, present results, interpret data, and draw conclusions regarding your work and contribution to your team.
Select appropriate methods and techniques in performing experiments.
Have strong analytical, organizational, and communication skills.
Collaborate to develop research methods and proactively seeks out others to discuss potential solutions to problems.
Use good verbal communication skills and interpersonal skills to provide insight into the processes used to best achieve results of assigned tasks.
You must be goal-oriented and be able to work independently in a collaborative team-oriented setting

Candidates should also be proficient in English.

Education
More than 2 years research experience (preferably in industry) with a BS degree in Molecular Biology or related scientific discipline.

Candidates interested in applying for this position should forward their CV to the following address: info@tespharma.com.

TES Pharma and École Polytechnique Fédérale de Lausanne (EPFL) Announce R&D Collaboration on Small Molecule Therapies for Metabolic Disorders and Age-Related Diseases – July 2015

PERUGIA, Italy and LAUSANNE, Switzerland, July 2, 2015

TES Pharma and EPFL announce a new research and development collaboration on novel small molecule modulators of the kynurenine pathway as therapies for metabolic disorders and age-related diseases.

TES Pharma   EPFL

The collaboration brings together TES Pharma, a research-based biotech company led by Professor Roberto Pellicciari (Scientific Co-Founder of Intercept Pharmaceuticals, Inc) with state of the art research facilities in Corciano (Perugia) and long running experience in modulators of the kynurenine pathway and metabolic disorder drug discovery, with the Laboratory of Integrative and Systems Physiology (LISP) at EPFL, led by Professor Johan Auwerx (Professor and Nestlé Chair in Energy Metabolism) pioneers in the role of NAD+ biosynthesis in metabolic disorders and ageing.

Professor Roberto Pellicciari President and CSO of TES Pharma said, “Combining our respective expertise provides an exciting platform for novel drug discovery with a world leader in metabolic disorders and ageing. “Taking forward small molecule therapies for these multi-faceted diseases requires detailed knowledge of the underlying basic biology, so we’re very excited about the opportunity work with LISP and Professor Auwerx to develop new disease-modifying therapies for these disorders.”

“The collaboration with TES Pharma capitalises on our interests in signalling and transcriptional events that underlie the pathogenesis of ageing and many metabolic diseases, and will pave the way for novel therapeutic agents for these diseases,” said Professor Johan Auwerx. “Our long-standing and fruitful collaboration with Professor Pellicciari will be an assurance for success!”

About TES Pharma

TES Pharma focuses on integrating in depth knowledge of drug design and chemistry, with systems and molecular biology to better design effective disease modifiers by bridging between academic – industrial environments with a network of world class centres of excellence that allows fuller exploitation of disease hypotheses and their conversion to novel and effective therapeutics. TES Pharma has proven expertise in innovative drug discovery, particularly in the areas of bile acids, nuclear receptors, and metabolic disorders

About The Laboratory of Integrative and Systems Physiology (LISP) at EPFL

The research of the Laboratory of Integrative and Systems Physiology (LISP) aims to understand how transcription factors and transcriptional cofactors, act as sensors for molecules of nutritional, metabolic or pharmacological origin. The research of the LISP contributed to our current understanding of how such transcriptional regulators change gene and protein expression patterns to control metabolic homeostasis. A recent focus of the laboratory has been on NAD+ biology, as it turns out that NAD+ is not only acting as a metabolic cofactor but also as a powerful signalling molecule with pleiotropic metabolic effects.

 /PRNewswire/ 

TES Pharma listed in the top 26 start-ups in Italy – Aug 2014

Startup italiane milionarie, ecco le magnifiche 26

LA LISTA

Superano il milione di euro di giro d’affari, sono soprattutto nel Nord (ma anche in Puglia e Sardegna) e spaziano dalla tecnologia digitale al farmaceutico, dalla consulenza online alla fabbricazione di strumenti e apparecchiature. Una piccola Paperopoli italiana dell’innovazione
di Luciana Maci
In Italia c’è un piccolo gruppo di startup milionarie. Sono 26 le startup innovative che, al 4 agosto 2014, risultavano aver superato la cifra-simbolo di un milione di euro di giro d’affari nell’ultimo anno di vita. È quanto emerge dai dati ufficiali delle Camere di Commercio, che indicano anche se il valore della produzione delle suddette imprese si è attestato tra gli uno e i due milioni di euro o se rientra nella fascia 2-5 milioni (qui i dati completi). Sono sparse per l’Italia – principalmente al Centro-Nord, ma ce ne sono in Puglia, Sardegna e una in Calabria- e si occupano di vari settori: dal digitale al farmaceutico, dalla comunicazione alla costruzione di aerei, dalle soluzioni tecnologiche eco-compatibili ai servizi di comparazione e consulenza online. Alcune sono aziende nate da professionisti di lungo corso, altre spin-off universitari. Ecco l’elenco delle startup della nostra piccola, innovativa Paperopoli.

Startup Italiane Millionarie